- Home
- KRNY vs MREO Comparison
KRNY vs MREO Comparison
Compare KRNY & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNY
- MREO
- Stock Information
- Founded
- KRNY 1884
- MREO 2015
- Country
- KRNY United States
- MREO United Kingdom
- Employees
- KRNY N/A
- MREO N/A
- Industry
- KRNY Savings Institutions
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- KRNY Finance
- MREO Health Care
- Exchange
- KRNY Nasdaq
- MREO Nasdaq
- Market Cap
- KRNY 381.4M
- MREO 369.2M
- IPO Year
- KRNY 2005
- MREO N/A
- Fundamental
- Price
- KRNY $6.18
- MREO $2.56
- Analyst Decision
- KRNY Buy
- MREO Strong Buy
- Analyst Count
- KRNY 2
- MREO 7
- Target Price
- KRNY $7.75
- MREO $7.71
- AVG Volume (30 Days)
- KRNY 382.1K
- MREO 1.8M
- Earning Date
- KRNY 04-24-2025
- MREO 05-14-2025
- Dividend Yield
- KRNY 7.30%
- MREO N/A
- EPS Growth
- KRNY N/A
- MREO N/A
- EPS
- KRNY N/A
- MREO N/A
- Revenue
- KRNY $148,070,000.00
- MREO N/A
- Revenue This Year
- KRNY $17.60
- MREO N/A
- Revenue Next Year
- KRNY $22.31
- MREO $61.92
- P/E Ratio
- KRNY N/A
- MREO N/A
- Revenue Growth
- KRNY N/A
- MREO N/A
- 52 Week Low
- KRNY $5.28
- MREO $1.58
- 52 Week High
- KRNY $8.59
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- KRNY 56.98
- MREO 59.81
- Support Level
- KRNY $5.81
- MREO $1.58
- Resistance Level
- KRNY $5.96
- MREO $2.37
- Average True Range (ATR)
- KRNY 0.29
- MREO 0.21
- MACD
- KRNY 0.07
- MREO 0.08
- Stochastic Oscillator
- KRNY 96.74
- MREO 92.61
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. It is also heavily into secured and unsecured business and consumer loans. The bank's primary source of income is net interest income.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).